Page last updated: 2024-12-04

dihydrolipoamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Dihydrolipoamide is a reduced form of lipoamide, a cofactor essential for several key metabolic pathways, including the pyruvate dehydrogenase complex (PDC) and the alpha-ketoglutarate dehydrogenase complex (KGDHC). It plays a crucial role in oxidative decarboxylation reactions, transferring electrons and acetyl groups during energy production. Dihydrolipoamide is synthesized from lipoic acid, a sulfur-containing fatty acid. The reduction of lipoamide to dihydrolipoamide is catalyzed by specific enzymes within the PDC and KGDHC, involving NADH as a reducing agent. Dihydrolipoamide is studied to understand its role in metabolism, investigate potential therapeutic targets for metabolic disorders, and explore its potential applications in biosensors and biofuel production. Its importance lies in its ability to facilitate the transfer of electrons and acyl groups, which are critical for energy production and biosynthesis.'

Cross-References

ID SourceID
PubMed CID663
CHEBI ID17694
SCHEMBL ID37411
MeSH IDM0050593

Synonyms (20)

Synonym
CHEBI:17694
6,8-dimercaptooctanamide
6,8-disulfanyloctanamide
3884-47-7
C00579
dihydrothioctamide
DIHYDROLIPOAMIDE ,
6,8-bis(sulfanyl)octanamide
octanamide, 6,8-dimercapto-
unii-8rf8an4jfl
8rf8an4jfl ,
SCHEMBL37411
6,8-bis-sulfanyloctanamide
6,8-disulfanyloctanimidic acid
LMFA08010019
6,8-dimercaptooctanoic acid amide
6,8-dimercapto-octanamide
Q3027880
DTXSID90863287
PD038094

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Prevention of the acute adverse effects of doxorubicin on myocardium may hinder the later development of cardiomyopathy."( Prevention of doxorubicin-induced acute cardiotoxicity by an experimental antioxidant compound.
Czopf, L; Deres, P; Habon, T; Halmosi, R; Hideg, K; Kalai, T; Kovacs, K; Palfi, A; Sumegi, B; Toth, A; Toth, K, 2005
)
0.33
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (4)

RoleDescription
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
cofactorAn organic molecule or ion (usually a metal ion) that is required by an enzyme for its activity. It may be attached either loosely (coenzyme) or tightly (prosthetic group).
Saccharomyces cerevisiae metaboliteAny fungal metabolite produced during a metabolic reaction in Baker's yeast (Saccharomyces cerevisiae).
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
dithiol
monocarboxylic acid amideA carboxamide derived from a monocarboxylic acid.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (30)

PathwayProteinsCompounds
Valine, Leucine, and Isoleucine Degradation2852
Pyruvate Metabolism2139
beta-Ketothiolase Deficiency2852
2-Methyl-3-hydroxybutyryl-CoA Dehydrogenase Deficiency2852
Propionic Acidemia2852
3-Hydroxy-3-methylglutaryl-CoA Lyase Deficiency2852
Maple Syrup Urine Disease2852
3-Methylcrotonyl-CoA Carboxylase Deficiency Type I2852
3-Methylglutaconic Aciduria Type I2852
3-Methylglutaconic Aciduria Type III2852
Methylmalonate Semialdehyde Dehydrogenase Deficiency2852
Methylmalonic Aciduria2852
Isovaleric Aciduria2852
Leigh Syndrome2139
Pyruvate Decarboxylase E1 Component Deficiency (PDHE1 Deficiency)2139
Pyruvate Dehydrogenase Complex Deficiency2139
3-Methylglutaconic Aciduria Type IV2852
3-Hydroxyisobutyric Acid Dehydrogenase Deficiency2852
3-Hydroxyisobutyric Aciduria2852
Isobutyryl-CoA Dehydrogenase Deficiency2852
Isovaleric Acidemia2852
Primary Hyperoxaluria II, PH22139
Pyruvate Kinase Deficiency2139
Glycolysis and Pyruvate Dehydrogenase2428
2-Methyl-3-hydroxybutryl-CoA Dehydrogenase Deficiency2952
Acetyl-CoA + Dihydro-lipoamide = CoA + 6-S-Acetyl-dihydro-lipoamide ( Pyruvate metabolism )24
Citrate cycle ( Citrate cycle )2129
Succinyl-CoA + Dihydro-lipoamide = CoA + S-Succinyl-dihydro-lipoamide ( Citrate cycle )14
NAD+ + Dihydro-lipoamide = NADH + Lipoamide ( Pyruvate metabolism )14
Pyruvate metabolism ( Pyruvate metabolism )3027

Research

Studies (45)

TimeframeStudies, This Drug (%)All Drugs %
pre-199016 (35.56)18.7374
1990's13 (28.89)18.2507
2000's8 (17.78)29.6817
2010's5 (11.11)24.3611
2020's3 (6.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 45.21

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index45.21 (24.57)
Research Supply Index3.83 (2.92)
Research Growth Index4.47 (4.65)
Search Engine Demand Index65.96 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (45.21)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (2.22%)6.00%
Case Studies1 (2.22%)4.05%
Observational0 (0.00%)0.25%
Other43 (95.56%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]